Mizagliflozin for Low Blood Sugar
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a treatment called mizagliflozin to determine its effects on individuals with post-bariatric hypoglycemia (PBH), a condition characterized by low blood sugar after eating. Researchers aim to discover if this treatment can reduce unwanted drops in blood sugar and related symptoms. Participants will receive varying doses to identify the most effective one. The trial seeks individuals who underwent gastric bypass surgery over six months ago and experience low blood sugar after meals. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group.
Will I have to stop taking my current medications?
The trial requires that you do not use insulin or medications that increase insulin production. If you are on these, you will need to stop taking them to participate.
Is there any evidence suggesting that mizagliflozin is likely to be safe for humans?
Research has shown that mizagliflozin is generally safe for people. Earlier studies found no specific side effects related to its mechanism, including symptoms like hypoglycemia, meaning it did not cause dangerously low blood sugar levels. In another study, one person had a low blood sugar reading but experienced no symptoms.
Overall, mizagliflozin appears well-tolerated. It is designed to help control blood sugar without causing major side effects. For those considering joining a trial for mizagliflozin, this research suggests that the treatment is relatively safe based on past studies.12345Why do researchers think this study treatment might be promising?
Mizagliflozin is unique because it targets low blood sugar differently than current treatments, like glucose tablets or gels, which provide direct sugar boosts. Mizagliflozin works by modulating renal glucose reabsorption, offering a novel mechanism that potentially stabilizes blood sugar levels more effectively over time. Researchers are excited about this treatment because it could provide a more consistent and sustained approach to managing low blood sugar, reducing the need for frequent interventions and enhancing overall glucose control.
What evidence suggests that mizagliflozin might be an effective treatment for low blood sugar?
Research shows that mizagliflozin, a type of medication, effectively lowers blood sugar and insulin levels after meals. Studies have demonstrated that it significantly reduces low blood sugar events without affecting blood sugar levels in those without low blood sugar. Additionally, mizagliflozin is safe for patients with constipation, with a low risk of causing low blood sugar. These findings suggest that mizagliflozin may help manage blood sugar levels after eating and reduce the risk of low blood sugar, making it a promising treatment for people with these issues. Participants in this trial will receive a placebo and two doses of encapsulated mizagliflozin over three dosing periods to further evaluate its effectiveness and safety.12678
Are You a Good Fit for This Trial?
This trial is for individuals who have had Roux-en-Y gastric bypass surgery over 6 months ago and are diagnosed with post-bariatric hypoglycemia (PBH). Participants must not be pregnant, using insulin or drugs that increase insulin release, and should not have other conditions causing low blood sugar.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive placebo and two doses of encapsulated mizagliflozin in a crossover fashion
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Mizagliflozin
- Placebo
Trial Overview
The study tests the effects of Mizagliflozin—a drug—on adverse events and how it affects blood sugar levels after eating in people with PBH. It's a phase 2 trial where participants will receive either Mizagliflozin or a placebo without knowing which one they're getting.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Subjects will receive placebo and two doses of encapsulated mizagliflozin over three dosing periods. Twice and three times daily dosing will be examined.
Subjects will receive placebo and two doses of encapsulated mizagliflozin over three dosing periods. Once and twice daily dosing will be examined.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vogenx, Inc.
Lead Sponsor
Citations
OR08-04 Efficacy and Safety of the SGLT1 Inhibitor ...
In conclusion, treatment with Mizagliflozin led to clinically meaningful improvements in postprandial glucose and insulin, and reductions in ...
Vogenx Announces Positive Results From Second Phase 2 ...
Mizagliflozin is effective in preventing hypoglycemic events without significantly impacting blood glucose levels in patients not experiencing hypoglycemia.
Effect of Mizagliflozin on Postprandial Plasma Glucose in ...
We reported that mizagliflozin showed favourable efficacy and safety for patients with functional constipation and the risk of hypoglycaemia would be low.
Study Results | NCT05541939 | Effect of Mizagliflozin on ...
The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure.
Vogenx Announces Positive Results From Second Phase 2 ...
These data suggest mizagliflozin is effective in preventing hypoglycemic events without significantly impacting blood glucose levels in ...
Safety and efficacy of the sodium-glucose cotransporter 1 ...
No specific adverse events related to the mechanism of action of mizagliflozin, such as hypoglycaemia-like symptoms, were observed. According to Rome III and IV ...
919.659.5677919.659.5677
To evaluate the safety, tolerability, and pharmacodynamics of two formulations of mizagliflozin with respect to postprandial plasma glucose ...
8.
researchgate.net
researchgate.net/publication/396795481_OR08-04_Efficacy_and_Safety_of_the_SGLT1_Inhibitor_Mizagliflozin_in_Patients_with_Post-Bariatric_HypoglycemiaOR08-04 Efficacy and Safety of the SGLT1 Inhibitor ...
Results Baseline frequency of hypoglycemic events, disability, and hypoglycemia-related worries were high. Symptom-triggered hypoglycemic events ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.